title: Direct-, fibroblast- and myoblast-mediated gene transfer to the anterior cruciate ligament.
abstract: The anterior cruciate ligament (ACL) has poor capabilities of healing. Maturation or "ligamentization" of the ACL following autograft or allograft reconstruction has been found slow and remains under investigation. In vitro and in vivo studies have shown that platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), and epidermal growth factor (EGF) have the potential to improve ligament healing. Gene therapy approaches may represent a new alternative in delivering these specific growth factors to the ACL. The aim of this study was to investigate the feasibility of three different gene therapy approaches (direct-, fibroblast-, and myoblast-mediated gene transfer) to the ACL. Rabbit myoblasts and ACL-fibroblasts were transduced with 5 x 10(7) recombinant adenoviral particles carrying the LacZ reporter gene (MOI = 50). Myoblasts and fibroblasts (1 x 10(6)) were each injected into the right ACL of 10 adult rabbits; direct injection of 5 x 10(7) adenoviral particles was performed in 10 other rabbits. The left side was used as sham. The beta-galactosidase production was revealed using the LacZ histochemical technique. The transduced fibroblasts and myoblasts were found in the ligament tissue and in the synovial tissue surrounding the ACL at 4, 7, 14, and 21 days postinjection. The myoblasts fused and formed myotubes in the ligament. The direct approach also allowed the transfer of the marker gene in the ligament at 4, 7, 21, and 42 days postinjection. X-gal staining revealed no expression of beta-galactosidase in the sham ligament. The presence of cells expressing the marker gene in the ACL opens up the possibility of delivering proteins (i.e., PDGF, TGF-beta, and EGF) capable of improving ACL healing and graft maturation. Furthermore, engineered myoblasts may mediate and accelerate the intraligament neovascularization. This new technology based on gene therapy and tissue engineering may allow a persistent expression of selected growth factors to enhance ACL healing following injury.
authors.affiliation: Department of Orthopaedic Surgery and Molecular Genetics and Biochemistry, Children's Hospital and University of Pittsburgh, Pittsburgh, PA 15261, USA.
authors.forename: J
authors.initials: J
authors.lastname: Menetrey
authors.forename: C
authors.initials: C
authors.lastname: Kasemkijwattana
authors.forename: C S
authors.initials: CS
authors.lastname: Day
authors.forename: P
authors.initials: P
authors.lastname: Bosch
authors.forename: F H
authors.initials: FH
authors.lastname: Fu
authors.forename: M S
authors.initials: MS
authors.lastname: Moreland
authors.forename: J
authors.initials: J
authors.lastname: Huard
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D016118:Anterior Cruciate Ligament / Q000166:cytology* / Q000378:metabolism; D000070598:Anterior Cruciate Ligament Injuries; D001187:Artificial Organs; D017690:Cell Transplantation; D003673:Defective Viruses / Q000235:genetics; D005240:Feasibility Studies; D005347:Fibroblasts / Q000378:metabolism* / Q000637:transplantation; D018014:Gene Transfer Techniques; D017930:Genes, Reporter; D005822:Genetic Vectors / Q000235:genetics; D007763:Lac Operon; D018482:Muscle, Skeletal / Q000166:cytology* / Q000378:metabolism; D018919:Neovascularization, Physiologic; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D013997:Time Factors; D014945:Wound Healing; D001616:beta-Galactosidase / Q000096:biosynthesis / Q000235:genetics
chemical_list: D011993:Recombinant Fusion Proteins; D001616:beta-Galactosidase